Trials / Unknown
UnknownNCT05004441
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer：HCCSC C02 Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Zhou Fuxiang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib Combined With mFOLFOX6/FOLFIRI | Fruquintinib (3mg) will be given p.o. daily |
Timeline
- Start date
- 2021-07-22
- Primary completion
- 2022-12-30
- Completion
- 2023-12-30
- First posted
- 2021-08-13
- Last updated
- 2022-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05004441. Inclusion in this directory is not an endorsement.